Champions Oncology (CSBR) Current Deferred Revenue (2011 - 2026)

Champions Oncology's Current Deferred Revenue history runs 16 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 8.46% year-over-year to $10.0 million; the TTM figure through Jan 2026 stood at $10.0 million (down 8.46% YoY), while the FY2025 annual figure was $15.4 million, up 27.69% from the prior year.
• Current Deferred Revenue was $10.0 million for Q1 2026 at Champions Oncology, down from $12.3 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $15.4 million in Q2 2025 to a low of $8.7 million in Q1 2022.
• Historically, Current Deferred Revenue has averaged $11.8 million across 5 years, with a median of $11.2 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue jumped 98.87% in 2022, then dropped 21.38% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $11.2 million in 2022, then rose by 16.07% to $13.0 million in 2023, then slipped by 21.38% to $10.2 million in 2024, then gained by 20.72% to $12.3 million in 2025, then declined by 18.97% to $10.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $10.0 million (Q1 2026), $12.3 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.